Clinical Trial Update: A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005) [Phase 2]

View source ↗

Summary

This trial update indicates that the Phase 2 study of MK0686 for postherpetic neuralgia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• MK0686

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neuralgia, Postherpetic | Phase 2 | Status: TERMINATED